Simon–Makuch 42-day landmark analyses showed a trend toward improved OS and RFS for patients who received alloHSCT after blinatumomab as compared with those who did not (Fig. 2e, f ).
← all excerpts
Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study.
1
—
—